Results 1 to 10 of about 2,872,365 (306)

Integrated Nicotine Replacement and Behavioral Support to Reduce Smoking in Opioid Agonist Therapy: A Randomized Clinical Trial.

JAMA Psychiatry
Key Points Question Can an integrated intervention combining nicotine replacement and brief behavioral support reduce the number of cigarettes smoked among patients receiving opioid agonist therapy?
Druckrey-Fiskaaen KT, Madebo T, Daltveit JT, Vold JH, Furulund E, Chalabianloo F, Gilje Lid T, Fadnes LT.   +7 more
europepmc   +3 more sources

Trajectories of retention in opioid agonist therapy in a Canadian setting

International Journal of Drug Policy, 2020
Background: Long-term engagement in opioid agonist therapy (OAT) has been consistently associated with reduced risk for morbidity and mortality in people with opioid use disorder (OUD).
Lindsey Richardson, Evan Wood, Thomas Kerr   +2 more
exaly   +6 more sources

Integrated exercise program in opioid agonist therapy clinics and effect on psychological distress: study protocol for a randomized controlled trial (BAReAktiv) [PDF]

Trials
Background Substance use disorder is associated with unhealthy lifestyle choices, resulting in adverse social and health consequences. People with opioid use disorder receiving opioid agonist therapy, in particular, have high morbidity and reduced ...
Einar Furulund, Tesfaye Madebo, Karl Trygve Druckrey-Fiskaaen, Jørn Henrik Vold, Mette Hegland Nordbotn, Eivin Dahl, Sindre M. Dyrstad, Torgeir Gilje Lid, Lars T. Fadnes, for the ATLAS4LAR study group   +9 more
doaj   +3 more sources

Comparing Canadian and United States opioid agonist therapy policies

International Journal of Drug Policy, 2019
Canada and the United States (U.S.) face an epidemic of opioid use disorder (OUD) and opioid overdose. The most effective OUD treatment is opioid agonist therapy (OAT)—buprenorphine (with and without naloxone) and methadone. Although federal approval for
Lauren Renee Gorfinkel, Dennis Mccarty, Jan Klimas   +2 more
exaly   +5 more sources

Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in England

International Journal of Drug Policy, 2022
Background The coronavirus pandemic resulted in many changes which had the potential to impact mortality related to opioid agonist therapy (OAT; methadone, buprenorphine), including changes in the prescribing and dispensing of OAT and patterns of drug ...
Nicola J. Kalk, Jennifer Scott, John Strang   +2 more
exaly   +2 more sources

High retention in an opioid agonist therapy project in Durban, South Africa: the role of best practice and social cohesion

Harm Reduction Journal, 2020
Background Moral conservatism within government and communities has resulted in a reluctance to support the provision of opioid agonist therapy for people with opioid use disorders in South Africa. In April 2017, South Africa’s first low-threshold opioid
Monique Marks, Andrew Scheibe, Shaun Shelly   +2 more
doaj   +2 more sources

Opioid agonist therapy engagement and crystal methamphetamine use: The impact of unregulated opioid use in Vancouver, Canada

International Journal of Drug Policy, 2022
Background Crystal methamphetamine use has substantially increased among people who use opioids in recent years, yet the impact of opioid agonist therapy (OAT) on crystal methamphetamine use remains poorly characterized.
Thomas Kerr, Paxton J Bach, Jeffrey Morgan   +2 more
exaly   +2 more sources

The Dose-Response Relationship between Opioid Agonist Therapy and Alterations in Pain Pathways in Patients with Opioid Use Disorders: A Cross-Sectional Study. [PDF]

CNS Drugs
The administration of opioids can be followed by enduring neuroplastic changes in the peripheral and central nervous systems. This remodeling can lead to opioid-induced hyperalgesia, causing an increased sensitivity to painful stimuli. The description of
Lang-Illievich K, Lang J, Rumpold-Seitlinger G, Dorn C, Brenna CTA, Klivinyi C, Bornemann-Cimenti H.   +6 more
europepmc   +2 more sources

Opioid analgesics for chronic noncancer pain in patients prescribed opioid agonist therapy or with opioid use disorder: A systematic review [PDF]

Canadian Journal of Pain
Background Opioid use disorder (OUD) is a growing public health concern in North America, often coexisting with chronic noncancer pain (CNCP). Managing both conditions presents unique challenges, highlighting the need for evidence to guide decision ...
Vahid Ashoorion, Tushar Sood, Shezel Muneer, Jason W. Busse, Danielle Rice, Jaris Swidrovich, Umair Majid, James Abesteh, Randi Q. Mao, Abhimanyu Sud   +9 more
doaj   +2 more sources

Changes in substance use in relation to opioid agonist therapy among people who use drugs in a Canadian setting

Drug and Alcohol Dependence, 2020
Background Although previous studies have shown that opioid agonist therapy (OAT) is linked to reductions in illicit opioid use, less is known about how OAT impacts the use of other psychoactive substances.
Hubert Wong, Evan Wood, Thomas Kerr
exaly   +2 more sources